| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML050 | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | XMD11-85h | GDSC1000 | pan-cancer | AAC | 0.027 | 0.6 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | PRIMA-1-Met | CTRPv2 | pan-cancer | AAC | -0.028 | 0.6 |
| mRNA | TL-2-105 | GDSC1000 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | GSK-1904529A | GDSC1000 | pan-cancer | AAC | 0.019 | 0.6 |
| mRNA | ZSTK474 | GDSC1000 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | BRD-K99006945 | CTRPv2 | pan-cancer | AAC | -0.03 | 0.6 |
| mRNA | BRD-K61166597 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | azacitidine | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |